Altis Biologics: From Labs to Riches

50,00 $

CASE STUDY. Doctor Nicolaas Duneas was in a quandary: as he sat in his dishevelled office at the Tshwane University of Technology (TUT), he pondered the future of his company Altis Biologics.

Clear

To buy a "Teaching License", you must register and be approved by our administration.

Description

Altis Biologics: From Labs to Riches: Abstract

Altis Biologics: From Labs to Riches is a case study by Boris Urban and Alison Gaylard.

Doctor Nicolaas Duneas was in a quandary: as he sat in his dishevelled office at the Tshwane University of Technology (TUT), he pondered the future of his company Altis Biologics. Founded in 2002, Altis was a small biotechnology company specialising in bone regeneration. Duneas was a trusted expert in his field, and Altis represented his life’s work. Now, in July 2009, the company was poised in a kind of no-man’s land. Duneas still needed to complete one more set of clinical trials before he could take his product to market, and for that he needed significant capital. Feeling like a very small fish in the big pond of global pharmaceuticals, Duneas wondered just how he was going to find the right funding and strategic partners to expand his business. Was he right to launch his product locally first? And was he being too ambitious by setting his sights on the overseas market?

Teaching objectives

This case was written to enable students to discuss and understand the principles, pitfalls and success factors for commercialisation of innovation.

Additional information

Year

Editor

Format

Industry
Institution

Language

Number of Pages

Size

Case centre numbering

Teaching Notes

License

,

Reviews

There are no reviews yet.

Be the first to review “Altis Biologics: From Labs to Riches”